Advertisement

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

Harriet S. Walter, Sandrine Jayne, Simon A. Rule, Guillaume Cartron, Franck Morschhauser, Salvador Macip, Lionel Karlin, Ceri Jones, Charles Herbaux, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles and Martin J.S. Dyer

Article Information

PubMed 

Print ISSN 
Online ISSN 

Article Versions


Contributors 
  • Harriet S. Walter, 1 Ernest and Helen Scott Haematological Research Institute, University of Leicester, United Kingdom;
  • Sandrine Jayne, 1 Ernest and Helen Scott Haematological Research Institute, University of Leicester, United Kingdom;
  • Simon A. Rule, 2 Department of Clinical Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom;
  • Guillaume Cartron, 3 Department of Clinical Hematology and Unit Mixte de Recherche, Centre National de la Recherche Scientifique (CNRS) 5235, CHRU, Montpelier, France;
  • Franck Morschhauser, 4 GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Univ. Lille, France;
  • Salvador Macip, 1 Ernest and Helen Scott Haematological Research Institute, University of Leicester, United Kingdom;
  • Lionel Karlin, 5 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hematologie, Pierre-Benite, Universite Claude Bernard Lyon 1, France;
  • Ceri Jones, 6 Cardiff CLL Research Group, School of Medicine, Heath Park, United Kingdom;
  • Charles Herbaux, 7 Department of Hematology, CHU Lille, France;
  • Philippe Quittet, 3 Department of Clinical Hematology and Unit Mixte de Recherche, Centre National de la Recherche Scientifique (CNRS) 5235, CHRU, Montpelier, France;
  • Nimish Shah, 2 Department of Clinical Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom;
  • Claire V. Hutchinson, 1 Ernest and Helen Scott Haematological Research Institute, University of Leicester, United Kingdom;
  • Christopher Fegan, 6 Cardiff CLL Research Group, School of Medicine, Heath Park, United Kingdom;
  • Yingsi Yang, 8 Gilead Sciences, Inc., Foster City, CA, United States
  • Siddhartha Mitra, 8 Gilead Sciences, Inc., Foster City, CA, United States
  • Gilles Salles, 5 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hematologie, Pierre-Benite, Universite Claude Bernard Lyon 1, France;
  • Martin J.S. Dyer, 1 Ernest and Helen Scott Haematological Research Institute, University of Leicester, United Kingdom;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output